Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run?

Natera is Druckenmiller’s top holding, with its stock up ~80% since the May 15, 2026 YTD low, and Druckenmiller increasing the position by 4% in Q2 2026. The company reported Q2 revenue of $752.8M (+37.7% YoY) and processed 1.04M tests (+22.4% YoY), with oncology MRD tests up 56% YoY to ~238,000. Growth momentum is supported by expanding Signatera approvals (U.S. bladder cancer companion diagnostic in May 2026, Japan colorectal approval in June, EU IVDR certification for solid tumors in July). The main offset is valuation: Natera remains unprofitable and trades at ~17x trailing 12-month sales, making the near-term entry point less attractive despite strong execution.

Analysis

NTRA is being priced like a near-monopoly in MRD, but the market is still ahead of the underlying cash conversion. In diagnostics, approvals matter far less than reimbursement, test utilization, and whether high-growth mix actually translates into operating leverage; at ~17x sales, the stock is already discounting a prolonged period of >30% growth plus margin inflection. That leaves limited room for any wobble in sequential adoption or payer timing.

Second-order, NTRA’s strength can pull capital away from other high-multiple diagnostics rather than expand the whole pie. If the next few quarters confirm commercial traction, EXAS and GH could still benefit from category validation, but if NTRA slows, the entire genomics/MRD bucket can de-rate together as investors reprice ‘innovation’ names from narrative to cash flow. The near-term catalyst path is 1-3 quarters; the structural question is whether international approvals become reimbursed revenue or just expensive option value.

Contrarian view: consensus is overcrediting regulatory milestones and underweighting reimbursement latency. The thesis breaks if oncology growth remains above ~35% and gross margin/operating loss improve for two consecutive quarters; otherwise, a rerating toward a lower-growth diagnostics multiple is plausible over 6-18 months. Druckenmiller ownership is a sentiment support, not a valuation floor.

Key Decisions for Investors

• Do not chase NTRA here; wait for a post-earnings pullback or evidence of reimbursement-driven margin expansion before adding. Risk/reward is poor after a large run because the multiple already prices in a near-flawless commercial ramp.
• If already long NTRA, hedge with a 3-6 month put spread financed against strength; use a sequential growth miss or a break below the 50-day moving average as the trigger to increase protection.
• Relative-value idea: long a basket of lower-multiple diagnostics/oncology names (EXAS, GH) and short NTRA over 1-2 quarters if you want sector exposure without paying peak-duration valuation. The trade works if the market keeps rewarding revenue quality over narrative.
• Set an alert for the next quarterly print: if payer/reimbursement commentary improves and consensus lifts FY growth, cover bearish hedges quickly. If utilization growth decelerates, expect multiple compression first and estimate revisions second.